|
MechanismFGFR2 antagonists |
|
|
|
|
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Dose-Ranging, Phase 2 Study to Evaluate the Efficacy and Safety of Different Doses of ZL-1102 Topical Gel (A Human VH IL-17A Antibody Fragment) in the Treatment of Chronic Plaque Psoriasis
A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Dose-Ranging, Phase 2 Study to Evaluate the Efficacy and Safety of Different Doses of ZL-1102 Topical gel (A Human VH IL-17A Antibody Fragment) in the Treatment of Chronic Plaque Psoriasis
An Open-label, Multicenter Study of ZL-1310 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects With Small Cell Lung Cancer
An Open-label, Multicenter Study of ZL-1310 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects with Small Cell Lung Cancer
一项在中国晚期胃癌或胃食管连接部癌且 FGFR2b 过表达的受试者中进行的 bemarituzumab 联合 mFOLFOX6 和纳武利尤单抗的 1 期研究
[Translation] A phase 1 study of bemarituzumab in combination with mFOLFOX6 and nivolumab in Chinese subjects with advanced gastric or gastroesophageal junction cancer with FGFR2b overexpression
主要目的:表征 bemarituzumab 的 PK 特征。
次要目的:评价 bemarituzumab+mFOLFOX6 和纳武利尤单抗的安全性和耐受性。评价 bemarituzumab 的 ADA。
探索性目的:评价 bemarituzumab+mFOLFOX6 和纳武利尤单抗的疗效。
[Translation] Primary objective: To characterize the PK profile of bemarituzumab.
Secondary objectives: To evaluate the safety and tolerability of bemarituzumab+mFOLFOX6 and nivolumab. Review of the ADA for bemarituzumab.
Exploratory purpose: To evaluate the efficacy of bemarituzumab+mFOLFOX6 and nivolumab.
100 Clinical Results associated with Zai Lab Ltd. (United States)
0 Patents (Medical) associated with Zai Lab Ltd. (United States)
100 Deals associated with Zai Lab Ltd. (United States)
100 Translational Medicine associated with Zai Lab Ltd. (United States)